Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21383331 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Terminated
Has Results
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
Condition: Lymphoma
Intervention: Biological: rituximab

Indicates status has not been verified in more than two years